Teachers Retirement System of The State of Kentucky trimmed its holdings in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 12.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 197,545 shares of the biotechnology company’s stock after selling 26,900 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Coherus Biosciences were worth $1,738,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of CHRS. The Manufacturers Life Insurance Company raised its position in Coherus Biosciences by 26.3% during the second quarter. The Manufacturers Life Insurance Company now owns 30,393 shares of the biotechnology company’s stock valued at $436,000 after buying an additional 6,327 shares during the period. California State Teachers Retirement System increased its position in Coherus Biosciences by 2.3% in the 2nd quarter. California State Teachers Retirement System now owns 67,940 shares of the biotechnology company’s stock worth $975,000 after purchasing an additional 1,500 shares during the last quarter. Wells Fargo & Company MN increased its position in Coherus Biosciences by 429.0% in the 3rd quarter. Wells Fargo & Company MN now owns 154,026 shares of the biotechnology company’s stock worth $2,056,000 after purchasing an additional 124,910 shares during the last quarter. Brown Advisory Inc. increased its position in Coherus Biosciences by 5.5% in the 3rd quarter. Brown Advisory Inc. now owns 594,021 shares of the biotechnology company’s stock worth $7,930,000 after purchasing an additional 31,211 shares during the last quarter. Finally, Temasek Holdings Private Ltd acquired a new position in Coherus Biosciences in the 3rd quarter worth about $87,524,000. 82.29% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have weighed in on the company. Maxim Group reaffirmed a “buy” rating and issued a $15.00 target price (down from $20.00) on shares of Coherus Biosciences in a research report on Friday, March 9th. BidaskClub raised Coherus Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Citigroup upped their target price on Coherus Biosciences from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, March 9th. Zacks Investment Research raised Coherus Biosciences from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Wednesday, January 3rd. Finally, ValuEngine raised Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $29.33.
Shares of Coherus Biosciences Inc (NASDAQ:CHRS) opened at $12.10 on Tuesday. The stock has a market capitalization of $751.77, a PE ratio of -2.66 and a beta of 3.62. Coherus Biosciences Inc has a 52 week low of $8.05 and a 52 week high of $24.70. The company has a debt-to-equity ratio of 3.33, a quick ratio of 5.12 and a current ratio of 5.12.
Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.02. Coherus Biosciences had a negative return on equity of 493.03% and a negative net margin of 73.89%. research analysts expect that Coherus Biosciences Inc will post -3 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.thestockobserver.com/2018/03/20/coherus-biosciences-inc-chrs-position-trimmed-by-teachers-retirement-system-of-the-state-of-kentucky.html.
About Coherus Biosciences
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus Biosciences Inc (NASDAQ:CHRS).
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.